2 results
Approved WMOCompleted
The central hypothesis of this project is that Aliskiren causes a substantial decrease in MSNA in hypertensive patients with CKD.
Approved WMORecruiting
To compare the progression free survival and neurotoxity of first line treatment with F-Nal-IRI, CapCar and CapOx.